| | | |

Proton Therapy for Mesothelioma: New Consensus Statement

proton therapy for mesothelioma

A group of international experts in radiation oncology say proton therapy for mesothelioma may be a safer alternative to standard radiotherapy. 

Proton therapy uses protons instead of photons to destroy mesothelioma tumor cells. 

The group evaluated both types of radiation therapy. They conclude that proton therapy for mesothelioma is less likely to damage the opposite lung and other organs. 

What is Proton Therapy?

Conventional radiation therapy for mesothelioma uses photons. A radiation oncologist delivers photons into the tumor with a linear accelerator. The photons or X-rays permanently damage the DNA. Damaged mesothelioma cells cannot grow and divide normally and the cells die. 

The downside of standard radiation therapy is that normal tissue absorbs some of the damaging photons, too. This limits how much radiation doctors can use. Even targeted radiotherapy like IMRT cannot prevent this. 

Proton therapy for mesothelioma works the same way. But proton particles behave differently than photons. There is some evidence that they cause more devastating and long-lasting DNA damage.  

Another difference with proton therapy for mesothelioma is how far the energy travels. Photons keep going after they pass through a mesothelioma tumor. They can damage organs on the other side. 

But protons release all their energy inside the cancer cells. This may be especially beneficial for pleural mesothelioma patients

Guidance for Clinicians

Pleural mesothelioma grows on the lining around the lungs. The tumors are close to vital organs like the heart, lungs, stomach, and kidneys. This makes it hard to deliver a cancer-killing dose with standard radiotherapy. Doctors have mostly used radiotherapy to shrink mesothelioma tumors before surgery. 

Proton therapy for mesothelioma may be safer and more effective. Doctors can use a higher dose without damaging other organs. The study group evaluated the clinical data on proton therapy to reach a consensus.

“The physical properties of proton therapy result in better sparing of normal tissues when treating the pleura, both in the post-pneumonectomy setting and the lung-intact setting,” says the new Consensus Statement. “Compared to photon radiation, there are dramatic reductions in dose to the contralateral lung, heart, liver, kidneys, and stomach.”

But proton therapy for mesothelioma is still challenging. One problem is the variety of different types of tissue in the chest. Another is the fact that organs like the lungs and heart are constantly moving. Movement and differing densities can make it hard to be precise.

Proton-based radiation is an evolving therapy.  Although the technology has existed for decades, it is only in the last few years that it has begun to get more attention from the cancer community as a potential treatment option. It is not yet widely available.

The new consensus statement on proton therapy for mesothelioma is designed to be a guide for doctors, insurance companies, and researchers. 

Source: 

Zeng, J, et al, “Consensus Statement on Proton Therapy in Mesothelioma”, Mary 24, 2020, Practical Radiation Oncology, Epub ahead of print, https://www.practicalradonc.org/article/S1879-8500(20)30117-X/pdf

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…